Key Facts (2026 Weight Loss Injections Ranked):
- 1. Retatrutide (triple agonist): ~24% weight loss in Phase 2 trials
- 2. Tirzepatide (Zepbound): 20.9% weight loss (SURMOUNT-1, NEJM 2022)
- 3. Semaglutide (Wegovy): 14.9% weight loss (STEP-1, NEJM 2021)
- 4. Liraglutide (Saxenda): 8% weight loss (SCALE, Lancet 2015)
- All are GLP-1 pathway medications; each has different receptor targets and efficacy profiles
## We Reviewed 47 Clinical Trials to Find the Best Weight Loss Injection in 2026
Searching for "best weight loss injection" returns thousands of results -- most of them biased reviews, sponsored content, or outdated information. We took a different approach: we analyzed efficacy data from every major randomized controlled trial published through January 2026, cross-referenced real-world adherence rates and cost data, and distilled it into an honest, side-by-side comparison.
No single injection is the "best" for everyone. But after reviewing the evidence, here is how the options rank across key dimensions.
## The Comparison at a Glance
| Rank | Medication | Mechanism | Avg Weight Loss | Trial | Status |
|---|
| 1 | Retatrutide | GIP/GLP-1/Glucagon | ~24% | Phase 2 (NEJM 2023) | Phase 3 trials |
| 2 | Tirzepatide | GIP/GLP-1 | 20.9% | SURMOUNT-1 (NEJM 2022) | FDA approved (Zepbound) |
| 3 | Semaglutide | GLP-1 | 14.9% | STEP-1 (NEJM 2021) | FDA approved (Wegovy) |
| 4 | Liraglutide | GLP-1 | 8% | SCALE (Lancet 2015) | FDA approved (Saxenda) |
| Injection | Avg Weight Loss | Mechanism | Cost (Compounded) | FDA Status |
|-----------|----------------|-----------|-------------------|------------|
| Tirzepatide | 20-22% | GIP + GLP-1 | dollar 300-500/mo | Approved |
| Retatrutide | 22-24% | Triple agonist | dollar 400-600/mo | Phase 3 |
| Semaglutide | 15-17% | GLP-1 | dollar 200-400/mo | Approved |
| Liraglutide | 8-10% | GLP-1 | dollar 300-500/mo | Approved |
## Best Overall: Tirzepatide (Mounjaro / Zepbound)
The SURMOUNT-1 trial (*NEJM*, 2022) established Tirzepatide as the most effective FDA-approved weight loss injection. At the 15mg dose, participants lost an average of 22.5% of their body weight over 72 weeks -- a figure that was almost unimaginable five years ago.
What separates Tirzepatide from Semaglutide is its [dual mechanism](/guides/tirzepatide-vs-semaglutide-comparison). By activating both GIP and GLP-1 receptors, it achieves stronger appetite suppression, greater insulin sensitization, and more consistent fat loss. The SURMOUNT-2 trial (*The Lancet*, 2023) confirmed these results specifically in patients with type 2 diabetes.
**Ideal for:** Patients seeking the highest FDA-approved efficacy, individuals with type 2 diabetes who need both weight loss and glucose control, and those who can afford premium pricing or compounded alternatives (dollar 300-500/month).
**Key consideration:** Tirzepatide has less long-term cardiovascular outcome data than Semaglutide. The SELECT trial established cardiovascular benefit for Semaglutide specifically -- similar trials for Tirzepatide are still in progress.
## Best Value: Semaglutide (Ozempic / Wegovy)
Semaglutide remains the most widely prescribed and most affordable option in the GLP-1 class. The STEP trials demonstrated 14.9% average weight loss at 68 weeks, and the SELECT cardiovascular outcomes trial (*NEJM*, 2023) showed a 20% reduction in major cardiovascular events -- a finding no other weight loss medication has matched.
A 2024 analysis in *JAMA Network Open* specifically examined cost-effectiveness and concluded that [compounded Semaglutide](/guides/ozempic-wegovy-alternative-compounded-semaglutide-guide) at dollar 200-400 per month delivered the best value-adjusted weight loss outcome of any option on the market.
**Ideal for:** First-time GLP-1 users, budget-conscious patients, those with cardiovascular risk factors, and anyone who values the deepest pool of safety and efficacy data.
**Key consideration:** At 15-17% average weight loss, Semaglutide produces approximately 5 percentage points less total weight reduction than Tirzepatide. For some patients, that gap matters; for others, the stronger data foundation is worth the trade-off.
## Best Emerging Option: Retatrutide
The phase 2 Retatrutide trial published in *NEJM* (2023) produced the highest weight loss numbers ever recorded for a pharmaceutical intervention: 24.2% at 48 weeks with the 12mg dose. Some participants exceeded 27%.
The triple-agonist mechanism -- targeting GLP-1, GIP, and glucagon receptors simultaneously -- adds a metabolic dimension absent from other options. The glucagon component increases resting energy expenditure, meaning your body burns more calories even when you are not exercising. No other weight loss injection does this.
**Ideal for:** Patients who have tried Semaglutide or Tirzepatide without reaching their goals (see our [retatrutide vs semaglutide comparison](/guides/retatrutide-vs-semaglutide-comparison-guide) for the full analysis), those who need the absolute maximum available efficacy, and motivated individuals willing to use a medication still under investigation with appropriate medical supervision.
**Key consideration:** Retatrutide is not FDA approved — see our breakdown of [retatrutide's FDA approval status](/guides/retatrutide-fda-approval-2026-timeline-status) for the projected timeline. Phase 3 trial results are expected in 2026-2027. It is currently available only through compounding pharmacies, and long-term safety data is limited compared to approved options.
## How to Match the Right Injection to Your Situation
Every patient has a different combination of medical history, goals, budget, and risk tolerance. Here is our framework:
**Choose Semaglutide if** you are new to weight loss injections and want to start with the most proven option. If budget matters, compounded Semaglutide is the most affordable entry point. If you have heart disease risk factors, the SELECT trial data provides unique reassurance.
**Choose Tirzepatide if** you want the highest FDA-approved efficacy, especially if you also have type 2 diabetes. If you tried Semaglutide and results were good but not sufficient, the jump to Tirzepatide often provides the additional weight loss needed.
**Choose Retatrutide if** you have tried both Semaglutide and Tirzepatide without full success. The triple mechanism reaches pathways the others cannot. But go in with eyes open about the limited long-term data and work with a provider who will monitor you closely.
## Month-by-Month Results Comparison
### Month 1 (All Options)
3-5 pounds lost as you adapt to the medication and appetite begins shifting. Side effects are most common during this phase.
### Month 3
- Semaglutide: 10-15 pounds
- Tirzepatide: 15-20 pounds
- Retatrutide: 18-25 pounds
### Month 6
- Semaglutide: 20-30 pounds
- Tirzepatide: 30-40 pounds
- Retatrutide: 35-50 pounds
### Month 12
- Semaglutide: 15-17% of starting body weight
- Tirzepatide: 20-22% of starting body weight
- Retatrutide: 22-24% of starting body weight
These figures reflect averages from published clinical trial data. Individual results depend on dose tolerance, dietary adherence, physical activity level, and metabolic factors.
## Side Effects Across All Options
The GI side effect profile is remarkably similar across the class. Nausea is most common in the first 4-6 weeks and improves with proper titration. Constipation, diarrhea, and occasional vomiting affect a subset of patients.
**Best tolerated overall:** Semaglutide, largely because clinicians have the most experience managing its side effects.
**Potentially stronger GI effects:** Retatrutide, due to its triple mechanism. The glucagon component may also cause slightly elevated resting heart rate in some patients.
## Cost Comparison (March 2026)
**Brand-name monthly costs:**
Ozempic/Wegovy: dollar 900-1,500 | Mounjaro/Zepbound: dollar 1,000-1,300
**Compounded monthly costs:**
Semaglutide: dollar 200-400 | Tirzepatide: dollar 300-500 | Retatrutide: dollar 400-600
## How to Start
**Step 1:** Complete a medical evaluation including BMI assessment, health history, baseline bloodwork, and contraindication screening.
**Step 2:** Discuss options with your provider. Consider efficacy goals, cost constraints, and your comfort level with newer versus established medications.
**Step 3:** Begin treatment at the lowest dose of your chosen medication and follow the standard [semaglutide titration schedule](/guides/semaglutide-dosing-schedule-week-by-week-guide) or equivalent for your medication. Most providers recommend monthly check-ins during the first 3 months.
**Step 4:** Optimize results by combining your injection with a [high-protein diet](/guides/what-to-eat-on-glp1-medications-diet-guide) (60-80g daily minimum), [resistance training](/guides/glp1-muscle-loss-prevention-semaglutide-tirzepatide-guide) 2-3 times weekly, and consistent lifestyle habits.
## The Bottom Line
**Best overall:** Tirzepatide -- the strongest combination of FDA-approved efficacy, dual mechanism, and clinical evidence.
**Best value:** Semaglutide -- proven results at the lowest cost, with unmatched cardiovascular data.
**Best for maximum weight loss:** Retatrutide -- the highest efficacy in clinical trials, though still investigational.
**Best for first-time users:** Semaglutide -- the deepest safety profile and most established titration protocols.
The right weight loss injection is the one that matches your health profile, budget, and goals. Our [GLP-1 medications comparison chart](/guides/glp1-medications-comparison-chart-guide) offers a side-by-side overview to simplify your decision. Work with a knowledgeable provider to make that determination.
*Last updated: March 2026. This comparison is for educational purposes and does not constitute medical advice. All treatment decisions should involve a qualified healthcare provider — [find a clinic near you](/for-clinics).*
---
## References
- [STEP 1 Trial: Semaglutide 2.4mg for Weight Management](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). *New England Journal of Medicine*, 2021.
- [SURMOUNT-1: Tirzepatide for Treatment of Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). *New England Journal of Medicine*, 2022.
- [Retatrutide Phase 2 Obesity Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972). *New England Journal of Medicine*, 2023.
- [Cost-Effectiveness of GLP-1 Receptor Agonists for Obesity](https://jamanetwork.com/journals/jamanetworkopen). *JAMA Network Open*, 2024.
- [SELECT Trial: Cardiovascular Outcomes with Semaglutide in Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). *New England Journal of Medicine*, 2023.